Phase 2 Proof-of-Activity Study of Oral Posaconazole in the Treatment of Asymptomatic Chronic Chagas Disease (Phase 2, Protocol No. P05267)

Trial Profile

Phase 2 Proof-of-Activity Study of Oral Posaconazole in the Treatment of Asymptomatic Chronic Chagas Disease (Phase 2, Protocol No. P05267)

Completed
Phase of Trial: Phase II

Latest Information Update: 24 May 2017

At a glance

  • Drugs Posaconazole (Primary) ; Benznidazole
  • Indications Chagas disease
  • Focus Therapeutic Use
  • Acronyms STOP CHAGAS
  • Sponsors Merck Sharp & Dohme
  • Most Recent Events

    • 28 Feb 2017 Primary endpoint (Percentage of Participants With a Successful Response as Measured by Qualitative Polymerase Chain Reaction) has not been met, according to results published in the Journal of the American College of Cardiology.
    • 28 Feb 2017 Results published in the Journal of the American College of Cardiology
    • 28 Jan 2015 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top